GRIN Therapeutics, a Neurvati Neurosciences company, is focused on developing novel treatment options for patients living with developmental and epileptic encephalopathies including GRIN-related Disorders, Tuberous Sclerosis Complex (TSC), and Focal Cortical Dysplasia (FCD). The company’s investigational product, radiprodil, is being evaluated in the Phase 1b Honeycomb study.